tiprankstipranks
Advertisement
Advertisement

SE:HNSA Stock Latest News

Hansa Biopharma Raises USD 30 Million via Convertible Notes to Back U.S. Imlifidase Launch
Company AnnouncementsHansa Biopharma Raises USD 30 Million via Convertible Notes to Back U.S. Imlifidase Launch
19d ago
Hansa Biopharma to Present Commercial Strategy at Redeye Life Science Event
PremiumCompany Announcements
Hansa Biopharma to Present Commercial Strategy at Redeye Life Science Event
26d ago
Hansa Biopharma to Spotlight Immunomodulatory Platform at DNB Carnegie Healthcare Conference
PremiumCompany Announcements
Hansa Biopharma to Spotlight Immunomodulatory Platform at DNB Carnegie Healthcare Conference
29d ago
Hansa Biopharma leadership to spotlight growth strategy at LSX Investival USA
PremiumCompany Announcements
Hansa Biopharma leadership to spotlight growth strategy at LSX Investival USA
30d ago
Hansa Biopharma to Spotlight Immunomodulatory Platform at Leerink Global Healthcare Conference
PremiumCompany Announcements
Hansa Biopharma to Spotlight Immunomodulatory Platform at Leerink Global Healthcare Conference
1M ago
Imlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile
PremiumRatingsImlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile
1M ago
Hansa Biopharma Secures FDA PDUFA Date for Imlifidase in High-Risk Kidney Transplant Patients
Premium
Company Announcements
Hansa Biopharma Secures FDA PDUFA Date for Imlifidase in High-Risk Kidney Transplant Patients
1M ago
Hansa Biopharma’s Anti-GBM Phase 3 Trial Termination: What Investors Should Know
Premium
Company Announcements
Hansa Biopharma’s Anti-GBM Phase 3 Trial Termination: What Investors Should Know
1M ago
HNSA
Hansa Biopharma to Present Corporate Strategy at TD Cowen Health Care Conference
PremiumCompany Announcements
Hansa Biopharma to Present Corporate Strategy at TD Cowen Health Care Conference
1M ago
Imlifidase’s Accelerated Approval Momentum and Long‑Term Graft Outcomes Support a Buy Rating on Hansa Biopharma
PremiumRatings
Imlifidase’s Accelerated Approval Momentum and Long‑Term Graft Outcomes Support a Buy Rating on Hansa Biopharma
2M ago
Hansa Biopharma Wins FDA Review Acceptance for Imlifidase Kidney Transplant Therapy
PremiumCompany Announcements
Hansa Biopharma Wins FDA Review Acceptance for Imlifidase Kidney Transplant Therapy
2M ago
Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright
PremiumThe Fly
Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright
2M ago
Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot
PremiumCompany AnnouncementsHansa Biopharma Earnings Call Marks Pivotal 2026 Pivot
2M ago
Hansa Biopharma Delivers Strong Q4 Growth and Files FDA Application for Imlifidase
Premium
Company Announcements
Hansa Biopharma Delivers Strong Q4 Growth and Files FDA Application for Imlifidase
2M ago
Hansa Biopharma Sets February Date for 2025 Year-End Results Call
Premium
Company Announcements
Hansa Biopharma Sets February Date for 2025 Year-End Results Call
2M ago
Hansa Biopharma Wins 2025 SwedenBIO Award as Late-Stage Pipeline Advances
PremiumCompany Announcements
Hansa Biopharma Wins 2025 SwedenBIO Award as Late-Stage Pipeline Advances
3M ago
Hansa Biopharma initiated with an Outperform at Wedbush
PremiumThe Fly
Hansa Biopharma initiated with an Outperform at Wedbush
3M ago
Hansa Biopharma Files FDA BLA for Imlifidase in High-Risk Kidney Transplant Patients
PremiumCompany Announcements
Hansa Biopharma Files FDA BLA for Imlifidase in High-Risk Kidney Transplant Patients
4M ago
Hansa Biopharma to Present at J.P. Morgan Healthcare Conference to Boost Investor Visibility
PremiumCompany Announcements
Hansa Biopharma to Present at J.P. Morgan Healthcare Conference to Boost Investor Visibility
4M ago
Hansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright
PremiumThe FlyHansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright
4M ago
Hansa Biopharma’s Phase 3 Trial for Anti-GBM Disease Shows Mixed Results
Premium
Company Announcements
Hansa Biopharma’s Phase 3 Trial for Anti-GBM Disease Shows Mixed Results
4M ago
Hansa Biopharma Strengthens European and International Operations
Premium
Company Announcements
Hansa Biopharma Strengthens European and International Operations
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >